The genetic testing company 23andMe is cutting 40% of its workforce and ending its therapeutics program as its stock price continues to plummet. CBS News correspondent Carter Evans has more on what this means for its customers.
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
Leave a Reply